Can J Hosp Pharm. 2009 Nov;62(6):457-63. doi: 10.4212/cjhp.v62i6.843.
Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.
The Canadian journal of hospital pharmacy
Eugenia Yeh, Glen Brown
Affiliations
Affiliations
- , BSc(Pharm), is with the Pharmacy, St Paul's Hospital, Vancouver, British Columbia.
PMID: 22478933
PMCID: PMC2827012 DOI: 10.4212/cjhp.v62i6.843
Abstract
BACKGROUND: Continuous renal replacement therapy is used to manage fluid and solute imbalances in critically ill patients but may affect the clearance of concurrently administered drugs. The impact of continuous renal replacement therapy on pharmacokinetics has been summarized, but previous reports have included studies involving various modes of therapy, filter membranes, and brands of dialyzers, which makes it difficult to apply the recommendations to individual patients. In Canada, continuous venovenous hemodiafiltration (CVVHDF) with a Prismaflex dialyzer machine (Gambro, Saint-Léonard, Quebec) and AN69 filter membranes is the most common mode of continuous renal replacement therapy for critically ill patients.
OBJECTIVE: To develop a set of dosage recommendations for commonly encountered medications used in treating critically ill patients who are undergoing CVVHDF with a Prismaflex dialyzer and AN69 filter membranes.
METHODS: A literature search was conducted to identify studies of the pharmacokinetics and disposition of drugs in patients undergoing CVVHDF via a Prismaflex dialyzer (sold under 3 brand names: Gambro, Hospal, and Prima) equipped with polyacrylonitrile (AN69) filter membranes. From each study, the mean total clearance of each study medication during CVVHDF was extracted and compared with clearance of the drug in patients not undergoing CVVHDF, to produce dosage guidelines for patients undergoing CVVHDF.
RESULTS: A total of 22 studies of 14 medications were included in the final review. For most of the drugs, the total clearance during CVVHDF was less than clearance in patients whose renal function was presumed to be normal. Fluconazole and moxifloxacin had greater total clearance during CVVHDF, but a dose adjustment during CVVHDF was deemed necessary only for fluconazole.
CONCLUSIONS: Dosing recommendations were created for concurrently administered drugs for patients undergoing treatment with this particular CVVHDF equipment. Patient-specific factors and clinical judgement should also be taken into account.
References
- Clin Pharmacokinet. 2006;45(7):649-63 - PubMed
- Intensive Care Med. 2007 Apr;33(4):660-6 - PubMed
- Antimicrob Agents Chemother. 1998 Sep;42(9):2421-4 - PubMed
- J Clin Pharmacol. 1980 Apr;20(4):197-201 - PubMed
- Antimicrob Agents Chemother. 1992 Oct;36(10):2085-92 - PubMed
- Crit Care Med. 2000 Mar;28(3):632-7 - PubMed
- J Antimicrob Chemother. 2004 Jul;54(1):269-70 - PubMed
- Antimicrob Agents Chemother. 1998 Aug;42(8):2060-5 - PubMed
- Antimicrob Agents Chemother. 1983 Jun;23(6):892-6 - PubMed
- Antimicrob Agents Chemother. 1984 Aug;26(2):208-10 - PubMed
- JAMA. 1995 Dec 6;274(21):1706-13 - PubMed
- J Clin Pharmacol. 2003 Dec;43(12):1329-40 - PubMed
- Crit Care. 2006 Feb;10(1):R26 - PubMed
- Antimicrob Agents Chemother. 1992 Mar;36(3):552-7 - PubMed
- Intensive Care Med. 1999 Jun;25(6):594-8 - PubMed
- Clin Ther. 2005 May;27(5):599-608 - PubMed
- J Clin Pharmacol. 1990 Oct;30(10):900-10 - PubMed
- J Antimicrob Chemother. 2004 Oct;54(4):780-4 - PubMed
- Antimicrob Agents Chemother. 2005 Nov;49(11):4814-5 - PubMed
- Antimicrob Agents Chemother. 2001 Oct;45(10):2949-54 - PubMed
- J Antimicrob Chemother. 2007 Nov;60(5):1085-90 - PubMed
- J Antimicrob Chemother. 2003 Dec;52(6):987-92 - PubMed
- Eur J Clin Pharmacol. 1979 Nov;16(5):331-4 - PubMed
- Intensive Care Med. 2001 Apr;27(4):665-72 - PubMed
- Antimicrob Agents Chemother. 1990 Apr;34(4):614-21 - PubMed
- Antimicrob Agents Chemother. 1978 Jul;14(1):40-4 - PubMed
- Antimicrob Agents Chemother. 1985 Nov;28(5):648-53 - PubMed
- Intensive Care Med. 1993;19(6):347-50 - PubMed
- J Infect Chemother. 2001 Mar;7(1):1-9 - PubMed
- Clin Ther. 1990 May-Jun;12(3):206-15 - PubMed
- Antimicrob Agents Chemother. 1992 Jul;36(7):1437-40 - PubMed
- Pharmacotherapy. 2002 Feb;22(2):175-83 - PubMed
- Antimicrob Agents Chemother. 1984 Nov;26(5):715-21 - PubMed
- Chemotherapy. 1993;39(1):6-12 - PubMed
- Thromb Haemost. 1995 Apr;73(4):630-40 - PubMed
- Eur J Clin Pharmacol. 2000 Dec;56(9-10):671-8 - PubMed
- J Clin Pharmacol. 2005 Apr;45(4):477-81 - PubMed
- Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:2-9 - PubMed
- Chemotherapy. 2007;53(3):194-201 - PubMed
- Pharmacotherapy. 2005 Oct;25(10):1310-8 - PubMed
- Clin Ther. 2005 Sep;27(9):1444-51 - PubMed
- Crit Care Med. 2008 Jan;36(1):296-327 - PubMed
- Antimicrob Agents Chemother. 2001 Nov;45(11):3148-55 - PubMed
- Clin Nephrol. 2007 May;67(5):267-84 - PubMed
- J Clin Pharmacol. 2005 Nov;45(11):1294-304 - PubMed
- Br J Clin Pharmacol. 2004 Sep;58(3):259-68 - PubMed
- Rev Infect Dis. 1981 Nov-Dec;3 suppl:S230-5 - PubMed
- Antimicrob Agents Chemother. 2005 Jun;49(6):2421-8 - PubMed
Publication Types